Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP545651.RAebsi4EG-xVaI3KAPXozRJxN0iTAdJqdVSn88EHEwL9Q130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP545651.RAebsi4EG-xVaI3KAPXozRJxN0iTAdJqdVSn88EHEwL9Q130_assertion type Assertion NP545651.RAebsi4EG-xVaI3KAPXozRJxN0iTAdJqdVSn88EHEwL9Q130_head.
- NP545651.RAebsi4EG-xVaI3KAPXozRJxN0iTAdJqdVSn88EHEwL9Q130_assertion description "[These encouraging observations led to the initiation of two large, prospective, placebo-controlled randomised clinical trials whose primary outcome is the prevention of type 2 diabetes: the DREAM (Diabetes REduction Approaches with ramipril and rosiglitazone Medications) trial with the ACE inhibitor ramipril and the NAVIGATOR (Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research) trial with the ARA valsartan.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP545651.RAebsi4EG-xVaI3KAPXozRJxN0iTAdJqdVSn88EHEwL9Q130_provenance.
- NP545651.RAebsi4EG-xVaI3KAPXozRJxN0iTAdJqdVSn88EHEwL9Q130_assertion evidence source_evidence_literature NP545651.RAebsi4EG-xVaI3KAPXozRJxN0iTAdJqdVSn88EHEwL9Q130_provenance.
- NP545651.RAebsi4EG-xVaI3KAPXozRJxN0iTAdJqdVSn88EHEwL9Q130_assertion SIO_000772 15516153 NP545651.RAebsi4EG-xVaI3KAPXozRJxN0iTAdJqdVSn88EHEwL9Q130_provenance.
- NP545651.RAebsi4EG-xVaI3KAPXozRJxN0iTAdJqdVSn88EHEwL9Q130_assertion wasDerivedFrom befree-20140225 NP545651.RAebsi4EG-xVaI3KAPXozRJxN0iTAdJqdVSn88EHEwL9Q130_provenance.
- NP545651.RAebsi4EG-xVaI3KAPXozRJxN0iTAdJqdVSn88EHEwL9Q130_assertion wasGeneratedBy ECO_0000203 NP545651.RAebsi4EG-xVaI3KAPXozRJxN0iTAdJqdVSn88EHEwL9Q130_provenance.